Benzyl isothiocyanate (BITC) induces apoptosis in ovarian cancer cells in vitro

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 4, 2006, Pages 287-300

  Kalkunte, Satyan ^a   Swamy, Narasimha ^a   Dizon, Don S ^a   Brard, Laurent ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Apoptosis; Benzyl isothiocyanate; Caspase activation; DNA fragmentation; Isothiocyanates; MAPK activation; Ovarian cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BENZYL ISOTHIOCYANATE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 8; CASPASE 9; CASPASE 9 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNINDEXED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 9; DNA REPLICATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HL-60 CELLS; HUMANS; ISOTHIOCYANATES; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS;

EID: 33749337250     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. 2004 American Cancer Society. Cancer statistics. CA Cancer J Clin 54:8-29, 2004.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20:1248-1259, 2002.
3. Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J, Holzel D. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 38:2435-2445, 2002.
4. Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: Mechanisms and current strategies. Br J Cancer 89:23-28, 2003.
5. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiol Biomarkers Prev 7:1091-1100, 1998.
6. Thornalley PJ. Isothiocyanates: mechanism of cancer chemopreventive action. Anticancer Drugs 13:331-338, 2002.
7. Meyer DJ, Crease DJ, Ketterer B. Forward and reverse catalysis and product sequestration by human glutathione S-transferases in the reaction of GSH with dietary aralkyl isothiocyanates. Biochem J 306:565-569, 1995.
8. Hecht SS. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. J Nutr 129:768-774, 1999.
9. Spitz MR, Duphorne CM, Detry MA, Pillow PC, Amos CI, Lei L, de Andrade M, Gu X, Hong WK, Wu X. Dietary intake of isothiocyanates: evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk. Cancer Epidemiol Biomarkers Prev 9:1017-1020, 2000.
10. Fowke JH, Chung FL, Jin F, Qi D, Cai Q, Conaway C, Cheng JR, Shu XO, Gao YT, Zheng W. Urinary isothiocyanate levels, brassica, and human breast cancer. Cancer Res 63:3980-3986, 2003.
11. Rosenberger G, Fuhrmann G, Grusch M, Fassl S, Elford HL, Smid K, Peters GJ, Szekeres T, Krupitza G. The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells. Life Sci 67:3131-3142, 2000.
12. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501, 1992.
13. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 281:1305-1308, 1998.
14. Green DR, Reed JC. Mitochondria and apoptosis. Science 281:1309-1312, 1998.
15. Datta SR, Brunei A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 13:2905-2927, 1999.
16. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105, 2000.
17. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73-81, 2001.
18. Lee S, Choi EJ, Jin C, Kim DH. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97:26-34, 2005.
19. Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Medical therapy of advanced malignant epithelial tumours of the ovary. Forum 10:323-332, 2000.
20. Keum YS, Jeong WS, Kong AN. Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat Res 555:191-202, 2004.
21. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 94:10367-10372, 1997.
22. Smith TK, Lund EK, Johnson IT. Inhibition of demethylhydrazine-induced aberrant crypt foci and induction of apoptosis in rat colon following oral administration of the glucosinolate sinigrin. Carcinogenesis 19:267-273, 1998.
23. Wattenberg LW. Inhibition of carcinogen induced neoplasia by sodium cyanate, tert-butyl isocyanate and benzyl isothiocyanate administered subsequent to carcinogen exposure. Cancer Res 41:2991-2994, 1981.
24. Miyoshi N, Uchida K, Osawa T, Nakamura Y. A link between benzyl isothiocyanate-induced cell cycle arrest and apoptosis: involvement of mitogen-activated protein kinases in the Bcl-2 phosphorylation. Cancer Res 64:2134-2142, 2004.
25. Zhang Y, Tang L, Gonzalez V. Selected isothiocyanates rapidly induce growth inhibition of cancer cells. Mol Cancer Ther 2:1045-1052, 2003.
26. Fimognari C, Nusse M, Berti F, Iori R, Cantelli-Forti G, Hrelia P. Isothiocyanates as novel cytotoxic and cytostatic agents: molecular pathway on human transformed and non-transformed cells. Biochem Pharmacol 68:1133-1138, 2004.
27. Getahun SM, Chung FL. Conversion of glucosinolates to isothiocyanates in humans after ingestion of cooked watercress. Cancer Epidemiol Biomarkers Prev 8:447-451, 1999.
28. Pintao AM, Pais MS, Coley H, Kelland LR, Judson IR. In vitro and in vivo antitumor activity of benzyl isothiocyanate: a natural product from Tropaeolum majus. Planta Med 61:233-236, 1995.
29. Yu R, Mandlekar S, Harvey KJ, Ucker DS, Kong AN. Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease activity. Cancer Res 58:402-408, 1998.
30. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15:26-290, 1999.
31. Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 70:398-403, 1998.
32. Kalli KR, Devine KE, Cabot MC, Arnt CR, Heldebrant MP, Svingen PA, Erlichman C, Hartmann LC, Conover CA, Kaufmann SH. Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. Mol Pharmacol 64:1434-1443, 2003.
33. McNeish IA, Bell S, McKay T, Tenev T, Marani M, Lemoine NR. Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway. Exp Cell Res 286:186-198, 2003.
34. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 333:336-343, 2005.
35. Garrington TP, Johnson GL. Organization and regulation of mitogen activated protein kinase signaling pathways. Curr Opin Cell Biol 11:211-218, 1999.
36. Seimiya H, Mashima T, Toho M, Tsuruo T. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem 272:4631-4636, 1997.
37. Sanchez-Perez I, Murguia JR, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533-540, 1998.
38. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 10:125-129, 2004.
39. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ. AKT1/PKBb kinase is frequently elevated in human cancers and its constitutive activation is required foroncogenic transformation in NIH3T3 cells. Am J Pathol 159:431-437, 2001.